FDA proposal to remove biosimilar interchangeability status in FY25

Home/Policies & Legislation | Posted 12/06/2024 post-comment0 Post your comment

In a major shift in regulatory policy, the US Food and Drug Administration (FDA) is calling on Congress to remove the interchangeability designation that has historically set biosimilars apart in the US market. Backed by the Biden administration, the FDA's new proposal would permit pharmacy-level substitution of biosimilar drugs for reference products without clinician recommendation. This would extend to all approved biosimilars, regardless of their interchangeability status.

01 AA007239

The FDA’s authority to designate biologicals as interchangeable was created by the Biologics Price Competition and Innovation Act, which came into force in 2010. The proposed plan would remove the current requirement for additional studies and/or clinical trials that can be requested by FDA to designate a biosimilar as interchangeable.  

In fact, on 6 November 2023, the U.S. Centers for Medicare & Medicaid Services (CMS) proposed a new rule that biosimilars can be substituted for the reference biologicals, even if these have not been deemed interchangeable by the FDA [1].

The FDA’s FY25 Legislative Proposals document claims that ‘the statutory distinction between biosimilars and interchangeable biosimilars has led to confusion and misunderstanding […] about the safety and effectiveness of biosimilars and about whether interchangeable biosimilars are safer or more effective than other biosimilars.’ The FY25 proposal would also deem approved biosimilars as interchangeable.

‘The proposal would reduce confusion and increase patient access to lower cost biosimilars. The Biosimilars Council looks forward to working with the administration and Congress to expand patient access to lower cost biosimilars’, said Craig Burton of Biosimilars Council and Association for Accessible Medicines (AAM).

Despite this, Mr Michael S Reilly, Executive Director of the Alliance for Safe Biologic Medicines (ASBM) argues, ‘This move is misguided, as biosimilars differ from generics and require individualized treatment plans. Physician confidence in biosimilars remains high, and the interchangeable standard has effectively built trust. Additionally, biosimilar uptake is influenced by formulary design, not interchangeability. Targeting pharmacy benefit managers practices could better support biosimilar adoption’ [2].

Related articles
Disruption in the US adalimumab market

FDA Guidance on Promotional Labelling and Advertising for Biologicals, Biosimilars and Interchangeables

Inflation Reduction Act explained

LATIN AMERICAN FORUM
The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: Actualización de los biosimilares aprobados por Health Canada en 2023

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

FORO LATINOAMERICANO
Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: Actualización de los biosimilares aprobados por Health Canada en 2023

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 

 

References
1. GaBI Online - Generics and Biosimilars Initiative. CMS proposes allowing Part D plans to switch biologicals to non-interchangeable biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Jun 12]. Available from: www.gabionline.net/policies-legislation/cms-proposes-allowing-part-d-plans-to-switch-biologicals-to-non-interchangeable-biosimilars
2. Reilly MS. Preserve the US interchangeable standard that has helped drive physician and patient confidence in biosimilars. Generics and Biosimilars Initiative Journal (GaBI Journal). 2024;13(2): Epub ahead of print.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2024 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
Panama embraces international pharmacovigilance standards
Pharmacovigilance V13F21
Home/Policies & Legislation Posted 09/07/2024
MHRA unveils strategy for regulating AI technologies
23 AA011020
Home/Policies & Legislation Posted 22/05/2024
Regulatory Certainty Strategy for biosimilars launched in Mexico
Regulation-V13H16
Home/Policies & Legislation Posted 09/04/2024
Strategic plans of ANVISA and COFEPRIS to advance health regulation
11 AA010165
Home/Policies & Legislation Posted 11/03/2024
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010